JAZZ vs TTMI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: JAZZ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JAZZ and TTMI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JAZZ and TTMI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Jazz Pharmaceuticals is an Ireland-domiciled specialty biopharmaceutical company that develops and markets treatments in neuroscience and oncology. Its largest products are Xywav and Xyrem (low-sodium and legacy oxybates for narcolepsy and idiopathic hypersomnia) and Epidiolex/Epidyolex (a cannabidiol treatment for rare epilepsies), which together anchor a neuroscience portfolio generating several billion dollars a year. Jazz has expanded aggressively into oncology through Zepzelca (small cell lung cancer), Rylaze (pediatric leukemia), Ziihera/zanidatamab (a HER2-directed bispecific antibody) and Modeyso (dordaviprone for diffuse glioma, added via the 2025 Chimerix acquisition).

Full JAZZ guide

TTM Technologies (Nasdaq: TTMI) makes technologically advanced printed circuit boards, RF and microwave components, and mission-systems assemblies. The name stands for time-to-market, reflecting a one-stop design, engineering, and manufacturing model. Its two anchor end markets are aerospace and defense (roughly 44% of sales, backed by a record backlog of about $1.61 billion as of early 2026 and multi-year programs like a $200 million Raytheon LTAMDS radar award) and data center and networking (about 36% of sales), where demand has surged with AI-driven interconnect complexity. The company has invested in domestic capacity, including a new Ultra-HDI plant in Syracuse, New York, and announced planned all-cash acquisitions of Swiss Technology Group and ILFA expected to close in the third quarter of 2026.

Full TTMI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JAZZ drivers: Sleep franchise durability; Oncology pivot and Ziihera.
• TTMI drivers: AI data center interconnect demand; Aerospace and defense backlog.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Jazz is concentrated in a few large products, so any acceleration of generic or branded competition against Xywav or Epidiolex could pressure revenue and the stock. For TTMI, pCB manufacturing has historically been cyclical and capital-intensive, and a slowdown in AI capital spending or defense budgets would pressure both anchor markets.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JAZZ if you believe its drivers more; TTMI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JAZZ and TTMI guides.

JAZZ. Jazz combines several billion dollars of high-margin drug revenue with strong non-GAAP earnings, yet trades at a comparatively low multiple relative to those profits. The gap reflects investor concern about patent cliffs and competition rather than current profitability. Net debt of roughly $3 billion means capital allocation and acquisition discipline matter to the equity story.

TTMI. TTM delivered record first-quarter 2026 net sales near $846 million with an adjusted EBITDA margin around 16%, and raised guidance on AI and defense demand. The stock re-rated sharply into 2026, reaching an all-time high near $224 in June before pulling back. Trailing and forward multiples sit well above TTM's multi-year averages, reflecting high growth expectations.

Headline figures (approximate, July 2026): JAZZ shows revenue (ttm) ~$4.3B, 2026 revenue guidance ~$4.25B to $4.5B, q1 2026 revenue ~$1.07B (up ~19% YoY), market cap ~$15B; TTMI shows revenue (ttm) ~$3.1B, fy2025 revenue ~$2.91B, q1 2026 revenue ~$846M (up ~30% YoY), q1 2026 non-gaap eps ~$0.75.

JAZZ and TTMI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JAZZ and TTMI exposure against your real portfolio. It is not an investment adviser.